HK1068140A1 - Xanthine phosphodiesterase v inhibitor polymorphs - Google Patents

Xanthine phosphodiesterase v inhibitor polymorphs

Info

Publication number
HK1068140A1
HK1068140A1 HK05101861A HK05101861A HK1068140A1 HK 1068140 A1 HK1068140 A1 HK 1068140A1 HK 05101861 A HK05101861 A HK 05101861A HK 05101861 A HK05101861 A HK 05101861A HK 1068140 A1 HK1068140 A1 HK 1068140A1
Authority
HK
Hong Kong
Prior art keywords
polymorphs
inhibitor
xanthine phosphodiesterase
phosphodiesterase
xanthine
Prior art date
Application number
HK05101861A
Other languages
English (en)
Inventor
Dahanukar Vilas
Nguyen Hoa
Orr Cecilia
Zhang Fucheng
Zavialov Ilia
Klopfer Kevin
Skell Jeffrey
Buchholz Albert
Boyle Craig
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1068140A1 publication Critical patent/HK1068140A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05101861A 2002-05-31 2005-03-03 Xanthine phosphodiesterase v inhibitor polymorphs HK1068140A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38448402P 2002-05-31 2002-05-31
PCT/US2003/016890 WO2003101991A1 (en) 2002-05-31 2003-05-30 Xanthine phosphodiesterase v inhibitor polymorphs

Publications (1)

Publication Number Publication Date
HK1068140A1 true HK1068140A1 (en) 2005-04-22

Family

ID=29712042

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101861A HK1068140A1 (en) 2002-05-31 2005-03-03 Xanthine phosphodiesterase v inhibitor polymorphs

Country Status (16)

Country Link
US (1) US7192962B2 (xx)
EP (1) EP1509524B1 (xx)
JP (1) JP2005529933A (xx)
CN (1) CN100384844C (xx)
AR (1) AR040233A1 (xx)
AT (1) ATE390425T1 (xx)
AU (1) AU2003249658A1 (xx)
CA (1) CA2486174A1 (xx)
DE (1) DE60319980T2 (xx)
ES (1) ES2299720T3 (xx)
HK (1) HK1068140A1 (xx)
MX (1) MXPA04011865A (xx)
PE (1) PE20040538A1 (xx)
TW (1) TW200404802A (xx)
WO (1) WO2003101991A1 (xx)
ZA (1) ZA200409644B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
KR100897218B1 (ko) * 2001-03-27 2009-05-14 다이닛본 스미토모 세이야꾸 가부시끼가이샤 결정성 이속사졸 유도체 및 그의 약학 제제
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
MXPA06001195A (es) 2003-07-31 2006-04-11 Schering Corp Metabolito de inhibidor de xantina fosfodiesterasa 5 y derivados del mismo utiles para el tratamiento de la disfuncion erectil.
AU2004292991A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
CN101102775A (zh) * 2004-11-18 2008-01-09 先灵公司 采用pdev抑制剂治疗充血性心衰的方法
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
PT1883397E (pt) * 2005-05-17 2010-02-23 Actelion Pharmaceuticals Ltd Comprimido dispersível de bosentano
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
IL133357A (en) * 1997-07-02 2003-12-10 Merck & Co Inc Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r)- (3,5-bis(trifluoromethyl) phenyl) ethoxy)-3-(s)-(4-fluoro) phenyl-4- (3-5(-oxo-1h, 4h-1,2,4-triazolo) methylmorpholine
AU743515B2 (en) * 1997-08-27 2002-01-24 Elanco Tiergesundheit Ag Dicyclanil polymorphs and hydrates and their preparation
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor

Also Published As

Publication number Publication date
CA2486174A1 (en) 2003-12-11
EP1509524A1 (en) 2005-03-02
AR040233A1 (es) 2005-03-23
WO2003101991A1 (en) 2003-12-11
ATE390425T1 (de) 2008-04-15
US7192962B2 (en) 2007-03-20
PE20040538A1 (es) 2004-08-30
TW200404802A (en) 2004-04-01
CN1656097A (zh) 2005-08-17
ZA200409644B (en) 2005-10-18
CN100384844C (zh) 2008-04-30
EP1509524B1 (en) 2008-03-26
AU2003249658A1 (en) 2003-12-19
DE60319980T2 (de) 2009-04-16
US20030232845A1 (en) 2003-12-18
MXPA04011865A (es) 2005-03-31
ES2299720T3 (es) 2008-06-01
DE60319980D1 (en) 2008-05-08
JP2005529933A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
HK1068140A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
IL154839A0 (en) Xanthine phosphodiesterase v inhibitors
DE50304867D1 (en) Thiazolderivate als phosphodiesterase iv-inhibtoren
HK1064668A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
SI1487805T1 (sl) Pirimidinski derivati
ZA200509319B (en) Quinoline derivatives as phosphodiesterase inhibitors
PL373649A1 (en) Kinase inhibitors
AU2003280680A1 (en) Xanthine compound
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
EP1558609A4 (en) KINASE INHIBITORS
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
EP1569907A4 (en) NICOTINAMIDE-BASED KINASE HEMMER
EP1570847A4 (en) PHOSPHODIESTERASE 10A HEMMER
AU2003244080A1 (en) Phosphodiesterase inhibitor
AU2003256323A8 (en) Sos1 inhibitors
AU2002350196A8 (en) Xanthine oxidase inhibition
GB2396837B (en) Workpiece finishing
GB0227443D0 (en) Pyrimidine derivatives
GB0205936D0 (en) Methylxanthine derivatives as Pl-3kinases inhibitors
GB0219304D0 (en) Pyrimidine derivatives
GB0219305D0 (en) Pyrimidine derivatives
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze
SI1567522T1 (sl) Pirimidinske spojine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120530